Medication info
Lyrica Capsule 150 mg (Pregabalin)

Lyrica Capsule 150 mg (Pregabalin)

Prescription medicationHard capsule
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Allico Pharmaceutical Co., Ltd.
Appearance
Hard capsules with a white or light yellow powder inside, with a white upper and lower part.
Packaging
Bottle packaging - 30 capsules/bottle
Approval status
Active

MFDS item code 201600892 · Approved 2016.02.16 · Insurance code 656004520

Summary

Main use
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of epileptic partial seizures
Who uses it
Adults · Children
Adult dosage
This drug is administered orally, with or without food, in 2 divided doses per day. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Doses exceeding 450 mg per day are not recommended, considering the dose-dependent adverse reactions. 4. Discontinuation of treatment Based on current clinical experience, if this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is excreted primarily by the kidneys as unchanged drug. The clearance of this drug is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered immediately after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration schedule Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children's dosage
7. Pediatric and adolescent patients Administration is not recommended because there are insufficient safety and efficacy data in children under 12 years and adolescent patients aged 12-17 years.

Ingredients

Manufacturer
Allico Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of epileptic partial seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures in patients with epilepsy, effective regardless of the presence or absence of secondary generalizations. Furthermore, it is used to treat symptoms of fibromyalgia. This is a medication that helps improve a variety of symptoms related to neurological disorders.

Dosage and Administration

Adult dosage

This drug is administered orally, with or without food, in 2 divided doses per day. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Doses exceeding 450 mg per day are not recommended, considering the dose-dependent adverse reactions. 4. Discontinuation of treatment Based on current clinical experience, if this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is excreted primarily by the kidneys as unchanged drug. The clearance of this drug is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered immediately after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration schedule Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Children's dosage

7. Pediatric and adolescent patients Administration is not recommended because there are insufficient safety and efficacy data in children under 12 years and adolescent patients aged 12-17 years.

Precautions

During treatment with this medication, suicidal thoughts or actions, symptoms of depression, and changes in mood and behavior may occur, and if such symptoms appear, you must immediately inform your doctor or pharmacist. Individuals with allergies to this medication or a history of hypersensitivity to its ingredients should not take it. In patients with diabetes, weight gain from this medication may necessitate adjustments to blood sugar control medication doses. If symptoms of angioedema like swelling around the face, mouth, or throat occur, stop taking the medication immediately and consult healthcare personnel. Elderly patients should be cautious as dizziness or drowsiness may arise from taking this medication, increasing the risk of falls or injury. Transient blurred vision or changes in vision may occur during treatment; if the symptoms persist, consult healthcare personnel. There is insufficient clinical evidence when switching from other antiepileptic medications to this drug, so careful consideration is required. Suddenly stopping this medication may result in withdrawal symptoms such as insomnia, headache, nausea, anxiety, so it should be gradually reduced following a doctor's instructions. Patients with a history of drug abuse may be at higher risk for misuse or dependence on this medication and should use it with special caution. Dosing adjustments may be necessary for patients with reduced kidney function. Patients with heart disease should consult healthcare personnel as there is a risk of developing congestive heart failure when taking this medication. Combining this medication with other central nervous system depressants, particularly opioid analgesics, may increase the risk of respiratory depression, so caution is advised. In early pregnancy, there may be a risk of congenital malformations; therefore, it should be avoided during pregnancy, and women of childbearing age should use effective contraception. During lactation, this medication may be passed into breast milk and affect the baby, so consideration should be given to stopping breastfeeding or the medication. Activities requiring concentration, such as driving or operating machinery, should only be undertaken after verifying the absence of dizziness or drowsiness post-ingestion of this medication. In case of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, requiring immediate medical attention. This medication should be stored out of the reach of children and should not be transferred to other containers. If severe rash, red spots, or blisters appear on the skin during treatment, stop taking the medication immediately and consult healthcare personnel.

Side effects

  • Suicidal impulses
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 188 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual dysesthesia
  • agitation
  • mood disturbances
  • emotional decrease
  • emotional increase
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of inhibition
  • apathy
  • ataxia
  • abnormal motor coordination
  • balance disorders
  • amnesia
  • attention disorder
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory decrease
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • taste loss
  • writing difficulties
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory decrease
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical cramps
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • altered sensation
  • fatigue
  • chest tightness
  • systemic edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reaction
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • fatigue
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • worsening of seizures
  • gastrointestinal disturbances
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • blood in stool
  • shock
  • anaphylaxis-like symptoms
  • skin and mucous membrane syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering, in a cool place between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

Hard capsules with a white or light yellow powder inside, with a white upper and lower part.

Package unit

Bottle packaging - 30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.